China Hepatitis A Virus Vaccine With High Antibody Response Manufacturer, Supplier, Factory

AIM Honesty Biopharmaceutical Co., Ltd. is a China manufacturer developing Hepatitis A Virus Vaccine With High Antibody Response based on human diploid cell technology. The product uses the hepatitis A virus Lv-8 strain cultured in KMB17 human diploid cells and is prepared through purification and inactivation procedures. With NMPA approval information including Approval Number S20153002, this vaccine is developed for hepatitis A prevention and immune protection applications among different age groups.

When evaluating hepatitis A vaccination products, immune response is one of the important factors considered by medical organizations. The ability of a vaccine to stimulate antibody production is closely related to antigen characteristics, production technology, and vaccination procedures. AIM Action Biopharmaceutical Co., Ltd. develops hepatitis A vaccine products using established human diploid cell technology, focusing on consistent antigen preparation and reliable immune response evaluation.

Immune Response Focus

Hepatitis A vaccination works by introducing specific viral antigens to activate the body's immune system. After vaccination, the immune system recognizes hepatitis A virus-related antigens and produces antibodies that help establish immune protection.

The antibody response of a vaccine is usually evaluated through indicators such as antibody conversion rate and geometric mean titer (GMT). These indicators help describe how effectively vaccinated individuals develop measurable antibody levels after immunization.

According to the product information provided by AIM Action, the hepatitis A inactivated vaccine shows good immune effects in both adults and children. The antibody conversion rate is similar to imported hepatitis A inactivated vaccines, while the geometric mean titer (GMT, mIU/mL) of antibodies is better than imported hepatitis A inactivated vaccines.

Technology Behind Immunity

The immune performance of a vaccine depends on multiple factors, including virus strain selection, cell substrate, antigen preparation, and manufacturing process control. AIM Action's hepatitis A vaccine uses the Lv-8 strain and KMB17 human diploid cell line as the foundation of production.

The Lv-8 strain was isolated and screened by the Kunming Institute during the 1988 Shanghai hepatitis A outbreak from a typical hepatitis A patient in Lüsi Town, Jiangsu Province. According to the provided product information, this strain has characteristics including stable properties, high virus yield, short replication cycle, and good immunogenicity.

The production process includes virus cultivation, harvesting, purification, ultrafiltration, concentration, chromatography purification, and formaldehyde inactivation. These controlled steps are used to prepare the final vaccine ingredient while maintaining the required antigen characteristics.

The main technical characteristics include:

1. Human diploid cell technology: The vaccine uses KMB17 human diploid cells as the culture substrate. This cell line was independently established by the Kunming Institute in 1974 and has been validated over a long period.

2. Stable virus strain selection: The Lv-8 hepatitis A virus strain provides the foundation for vaccine production with characteristics described in the provided product information.

3. Controlled inactivation process: Formaldehyde solution is added after purification procedures to complete virus inactivation and prepare the vaccine product.

Antibody Performance Reference

Antibody response information helps explain vaccine performance, but immune evaluation should always be understood together with manufacturing technology, dosage design, and vaccination requirements. Different products may use different evaluation methods, so comparing complete product information provides a more accurate understanding.

Product Specifications

Clear dosage specifications are important for different immunization applications. AIM Action provides separate dosage options according to age groups, allowing healthcare providers to select the appropriate formulation based on vaccination requirements.

For administration, the vaccine should be shaken well before use and administered intramuscularly at the deltoid muscle attachment site on the outer side of the upper arm according to professional vaccination guidance.

Immunization Applications

Hepatitis A prevention requires vaccination strategies that consider population characteristics, health management goals, and practical administration requirements. A vaccine with clear dosage information and established manufacturing technology can support different immunization scenarios, including childhood vaccination and adult preventive healthcare programs.

Hepatitis A Virus Vaccine With High Antibody Response is designed for active immunization against hepatitis A virus by stimulating the body's immune system to produce specific antibodies. The product can be applied in different healthcare environments where hepatitis A prevention is required.

Common application considerations include:

1. Childhood immunization: Children may have different vaccination requirements compared with adults. The availability of pediatric dosage specifications helps healthcare providers arrange suitable immunization procedures for younger populations.

2. Adult preventive vaccination: Adult vaccination programs require products with clear dosage information and established administration procedures to support effective health management.

3. Public health programs: Hepatitis A vaccination is an important measure for reducing infection risks and improving population immunity in areas where vaccination programs are implemented.

Manufacturing Quality

Vaccine quality depends on every stage of production, from strain selection and cell culture to purification and final preparation. AIM Action Biopharmaceutical Co., Ltd. follows a controlled manufacturing process for its hepatitis A vaccine products based on human diploid cell technology.

The production process starts with cultivation of the hepatitis A virus Lv-8 strain in KMB17 human diploid cells. After virus harvesting, the suspension is purified, concentrated, and processed through chromatography procedures. Formaldehyde solution is then added for inactivation to prepare the final vaccine ingredient.

The manufacturing characteristics include:

1. Defined production materials: The vaccine production uses a documented human diploid cell substrate and identified hepatitis A virus strain.

2. Process control: Multiple production steps, including purification and inactivation, are used to prepare the final vaccine product.

3. Product consistency: Standardized manufacturing procedures help maintain stable product characteristics between batches.

Storage And Handling

Correct storage conditions are essential for maintaining vaccine quality during transportation and use. According to the provided product information, the hepatitis A vaccine should be stored and transported at 2-8℃ and protected from light.

Following appropriate cold chain management and handling procedures helps maintain the intended performance of the vaccine throughout its lifecycle.

Why Choose AIM

Selecting a hepatitis A vaccine requires attention to scientific background, production technology, and product information transparency. AIM Action Biopharmaceutical Co., Ltd. focuses on vaccine research and manufacturing, with hepatitis A vaccine products developed using human diploid cell technology.

The company background and product development experience provide a foundation for organizations looking for vaccine products with documented production processes and technical information.

The reasons to consider AIM Action's vaccine include:

1. Professional vaccine development experience: AIM Vaccine focuses on human vaccine research, development, and manufacturing.

2. Established technical platform: The hepatitis A vaccine is based on KMB17 human diploid cell technology and Lv-8 strain cultivation.

3. Complete product information: Product specifications, dosage guidance, storage requirements, and manufacturing details are clearly provided.

FAQ

Q: What does antibody response mean for a hepatitis A vaccine?

A: Antibody response refers to the immune reaction generated after vaccination. The body recognizes vaccine-related antigens and produces antibodies that contribute to immune protection against hepatitis A virus.

Q: How is the immune response evaluated?

A: Immune response can be evaluated through indicators such as antibody conversion rate and geometric mean titer (GMT). These measurements help describe antibody production after vaccination.

Q: What technology is used to manufacture this hepatitis A vaccine?

A: The vaccine is manufactured using human diploid cell technology. The hepatitis A virus Lv-8 strain is cultured in KMB17 human diploid cells and processed through purification and inactivation procedures.

Q: What is the difference between pediatric and adult dosage?

A: The pediatric dosage is 0.5ml containing 320 EU of hepatitis A virus antigen, while the adult dosage is 1.0ml containing 640 EU of hepatitis A virus antigen.

Q: How long can the vaccine be stored?

A: According to the provided product information, the validity period is 36 months when stored under the recommended conditions of 2-8℃ and protected from light.

Q: Why is human diploid cell technology used?

A: Human diploid cell technology provides a controlled substrate for vaccine production. KMB17 human diploid cells have been used as the culture substrate for developing this hepatitis A vaccine.